Cargando…

Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice

Introduction: Capecitabine is a widely prescribed oral anticancer agent. We studied medication adherence and explored its use in daily practice from a patients' perspective. Patients and Methods: Patients (n = 92) starting capecitabine were followed up to five 3-week cycles. Adherence was asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timmers, Lonneke, Boons, Christel C. L. M., Mangnus, Dirk, Van de Ven, Peter M., Van den Berg, Pieter H., Beeker, Aart, Swart, Eleonora L., Honeywell, Richard J., Peters, Godefridus J., Boven, Epie, Hugtenburg, Jacqueline G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030243/ https://www.ncbi.nlm.nih.gov/pubmed/27708578 http://dx.doi.org/10.3389/fphar.2016.00310

Ejemplares similares

The use of capecitabine in daily practice: a study on adherence and patients’ experiences
por: Timmers, Lonneke, et al.
Publicado: (2012)

The use of erlotinib in daily practice: a study on adherence and patients' experiences
por: Timmers, Lonneke, et al.
Publicado: (2011)

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
por: Timmers, Lonneke, et al.
Publicado: (2015)

Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia
por: Boons, Christel CLM, et al.
Publicado: (2014)

Patient satisfaction with information on oral anticancer agent use
por: Boons, Christel C. L. M., et al.
Publicado: (2017)

Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists
por: Timmers, Lonneke, et al.
Publicado: (2017)

The impact of cardiovascular medication use on patients’ daily lives: a cross-sectional study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study
por: En‐nasery ‐ de Heer, Selma, et al.
Publicado: (2022)

Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions
por: Hugtenburg, Jacqueline G, et al.
Publicado: (2013)

Effectiveness of a Patient-Tailored, Pharmacist-Led Intervention Program to Enhance Adherence to Antihypertensive Medication: The CATI Study
por: van der Laan, Danielle M., et al.
Publicado: (2018)

Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden
por: Boons, Christel C. L. M., et al.
Publicado: (2020)

Implementation fidelity of an intervention programme to enhance adherence to antihypertensive medication in Dutch community pharmacies
por: van der Laan, Danielle M., et al.
Publicado: (2019)

The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial
por: van der Laan, Danielle M., et al.
Publicado: (2017)

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
por: Peters, Godefridus J., et al.
Publicado: (2019)

The Cost-Effectiveness of an Intervention Program to Enhance Adherence to Antihypertensive Medication in Comparison With Usual Care in Community Pharmacies
por: Bosmans, Judith E., et al.
Publicado: (2019)

Factors Associated With Nonadherence to Cardiovascular Medications: A Cross-sectional Study
por: van der Laan, Danielle M., et al.
Publicado: (2019)

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines
por: Noordhuis, Paul, et al.
Publicado: (2019)

Optimal treatment of opioid induced constipation in daily clinical practice – an observational study
por: Neefjes, Elisabeth C. W., et al.
Publicado: (2019)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method
por: van Leeuwen, Roelof WF, et al.
Publicado: (2010)

Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
por: Adema, Auke D, et al.
Publicado: (2014)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
por: Adema, Auke D., et al.
Publicado: (2011)

Capecitabine-Associated Terminal Ileitis
por: van Hellemond, Irene E.G., et al.
Publicado: (2018)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes
por: Kruger, Dinja T., et al.
Publicado: (2020)

Targeted therapies in renal cell cancer: recent developments in imaging
por: van der Veldt, Astrid A. M., et al.
Publicado: (2010)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Capecitabine-induced Leukoencephalopathy
por: Yoshimura, Kenji, et al.
Publicado: (2018)

Capecitabine-Induced Enterocolitis
por: Khan, Muzammil, et al.
Publicado: (2022)

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
por: Mammatas, L. H., et al.
Publicado: (2020)

Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[(18)F]fluorothymidine Positron Emission Tomography
por: Frings, Virginie, et al.
Publicado: (2013)

Severe hypertriglyceridaemia during treatment with capecitabine
por: Javot, L, et al.
Publicado: (2011)

Ileitis Secondary to Oral Capecitabine Treatment?
por: Radwan, Rami, et al.
Publicado: (2012)

Basic Fibroblast Growth Factor-Mediated Overexpression of Vascular Endothelial Growth Factor in 1F6 Human Melanoma Cells is Regulated by Activation of PI-3K and p38 MAPK
por: Fontijn, Dennis, et al.
Publicado: (2009)

Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care
por: Simons, Sven, et al.
Publicado: (2010)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences
por: Kruger, Dinja T., et al.
Publicado: (2018)

Capecitabine in the management of colorectal cancer
por: Hirsch, Bradford R, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_d1fa9q8tet6gj216js32s554ia